Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase
Drug Metabolism and Disposition · 2025-08 · 53 (8) · 100107
DOI: 10.1016/j.dmd.2025.100107 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025-08. Verfasst von Nicola Colclough und 19 weiteren Autor:innen. Beteiligte Einrichtung: DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. Electronic address: Nicola.Colclough@astrazeneca.com. Hauptthemen laut MEDLINE: Aldehyde Oxidase, Brain, Protein Kinase Inhibitors, Ataxia Telangiectasia Mutated Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: AstraZeneca PLC.
Abstract (Originalsprache)
AZD1390 was identified as a highly potent, selective, small-molecule inhibitor of ataxia-telangiectasia mutated kinase for use in combination with irradiation in the treatment of glioblastoma multiforme. Metabolism profiling in human hepatocytes and cytosol indicated that AZD1390 is a substrate for aldehyde oxidase (AO). Recognizing the historic failure of several AO substrates as therapeutics due to high first-pass hepatic extraction and subsequent low oral bioavailability, AZD1390 was benchmarked against a range of known AO substrates in human liver cytosol and hepatocytes. This data established AZD1390 clearance was likely to be high, approaching liver blood flow. Physiologically based pharmacokinetic (PBPK) simulations of animal PK predicted a high human volume of distribution for this monobase (∼19 L/kg). Together with a predicted complete fraction absorbed, this indicated an acceptable human oral profile to support sufficient target engagement was achievable. Whilst acknowledging a degree of uncertainty and risk for this AO substrate, AZD1390 was progressed into the clinic to assess human exposure. Analysis of plasma from patients following a single oral AZD1390 dose of 40 mg confirmed the presence of a major AO dependent metabolite (M10) at comparable levels to AZD1390. The clinical oral PK of AZD1390 was comparable to the simulated high clearance (15-20 mL/min/kg) profiles and supported continued progression of AZD1390. Furthermore, AZD1390 has shown brain penetrance in healthy volunteer positron emission tomography studies and is currently in glioblastoma multiforme clinical trials. This work demonstrates AO substrates with suitable properties can achieve acceptable human PK. SIGNIFICANCE STATEMENT: Several aldehyde oxidase (AO) substrates have failed in early clinical development due to low oral bioavailability. This case example demonstrates that despite the lack of relevant translational pharmacokinetics information from animals, via careful human in vitro benchmarking, certain AO substrates with suitable properties can be progressed and generate acceptable oral clinical pharmacokinetics. AZD1390 is a successful case example of prosecuting an AO substrate in the clinic after many documented failures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. Electronic address: Nicola.Colclough@astrazeneca.com.
- DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
- Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
- Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
- Clinical Pharmacology and Safety Sciences, Animal Sciences & Technology R&D, AstraZeneca, Boston, Massachusetts.
- DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts.
Förderung
- AstraZeneca PLC
Zitieren
APA
Colclough, N., Orton, A. L., Martin, S., Wild, M., Reddy, V. P., Lenz, E., Markandu, R., Wilson, J., Fan, C., Potter, J., Dai, D., Chan, C., Roberts, J., Xue, A., Pop-Damkov, P., Sykes, A., Jones, B., Hunt, T. A., Pike, K. G., & McGinnity, D. F. (2025). Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase. Drug Metabolism and Disposition, 53(8), 100107. https://doi.org/10.1016/j.dmd.2025.100107
Vancouver
Colclough N, Orton AL, Martin S, Wild M, Reddy VP, Lenz E, et al. Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase. Drug Metabolism and Disposition. 2025;53(8):100107. doi:10.1016/j.dmd.2025.100107
BibTeX
@article{Colclough2025,
author = {Colclough, Nicola and Orton, Alexandra L and Martin, Scott and Wild, Martin and Reddy, Venkatesh Pilla and Lenz, Eva and Markandu, Roshini and Wilson, Joanne and Fan, Chunling and Potter, Julian and Dai, David and Chan, Christina and Roberts, Jennie and Xue, Aixiang and Pop-Damkov, Petar and Sykes, Andy and Jones, Barry and Hunt, Thomas A and Pike, Kurt G and McGinnity, Dermot F},
title = {Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase},
journal = {Drug Metabolism and Disposition},
year = {2025},
volume = {53},
number = {8},
pages = {100107},
doi = {10.1016/j.dmd.2025.100107}
}
EUVIMED